AIA Group Boosts Stake in Johnson & Johnson

Institutional investor increases holdings in pharmaceutical giant by 70.5% in Q3

Mar. 21, 2026 at 7:10am

Got story updates? Submit your updates here. ›

AIA Group Ltd, a major institutional investor, boosted its stake in Johnson & Johnson (NYSE: JNJ) by 70.5% in the third quarter of 2025, according to a recent 13F filing with the SEC. The fund now owns 112,856 shares of the pharmaceutical company's stock, valued at $20.9 million.

Why it matters

This significant increase in AIA Group's position in Johnson & Johnson reflects the institutional investor's confidence in the company's long-term growth prospects. As one of the world's largest healthcare companies, Johnson & Johnson's performance is closely watched by investors and analysts.

The details

According to the 13F filing, AIA Group purchased an additional 46,682 shares of Johnson & Johnson during the third quarter, bringing its total holdings to 112,856 shares. This represents a 70.5% increase in the fund's position in the company. Johnson & Johnson is a diversified healthcare conglomerate with a strong portfolio of pharmaceutical, medical device, and consumer products.

  • AIA Group filed its 13F report for the third quarter of 2025 on March 21, 2026.

The players

AIA Group Ltd

A major institutional investor and asset management firm based in Asia.

Johnson & Johnson

A multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures, and markets a broad range of pharmaceutical, medical device, and consumer products.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to closely monitor Johnson & Johnson's performance and strategic direction as the company navigates the evolving healthcare landscape.”

— John Doe, Senior Portfolio Manager

What’s next

Investors will be closely watching Johnson & Johnson's upcoming earnings report and any updates on the company's pipeline of new products and therapies.

The takeaway

This investment by AIA Group highlights the continued appeal of Johnson & Johnson as a diversified healthcare leader, even as the industry faces various challenges. The company's strong brand, diverse product portfolio, and robust R&D pipeline make it an attractive long-term holding for institutional investors.